BIIB Biogen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIIB

Price (delayed)

$199.01

Market cap

$28.98B

P/E Ratio

24.72

Dividend/share

N/A

EPS

$8.05

Enterprise value

$34.85B

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights
The equity has grown by 10% YoY and by 2.8% from the previous quarter
The company's quick ratio has shrunk by 59% YoY but it rose by 3.3% QoQ
Biogen's debt has decreased by 5% from the previous quarter but it has increased by 5% YoY
The EPS has plunged by 63% YoY
Biogen's net income has shrunk by 63% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.biogen.com/
Peers: AMGN GILD PFE ABBV

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
145.6M
Market cap
$28.98B
Enterprise value
$34.85B
Valuations
Price to earnings (P/E)
24.72
Price to book (P/B)
1.9
Price to sales (P/S)
2.99
EV/EBIT
26.35
EV/EBITDA
18.81
EV/Sales
3.61
Earnings
Revenue
$9.66B
EBIT
$1.32B
EBITDA
$1.85B
Free cash flow
$1.28B
Per share
EPS
$8.05
Free cash flow per share
$8.85
Book value per share
$104.66
Revenue per share
$66.55
TBVPS
$83.03
Balance sheet
Total assets
$26.57B
Total liabilities
$11.35B
Debt
$6.95B
Equity
$15.21B
Working capital
$3.53B
Liquidity
Debt to equity
0.46
Current ratio
2.1
Quick ratio
0.95
Net debt/EBITDA
3.17
Margins
EBITDA margin
19.2%
Gross margin
75%
Net margin
12.1%
Operating margin
13.7%
Efficiency
Return on assets
4.4%
Return on equity
7.9%
Return on invested capital
8.4%
Return on capital employed
5.7%
Return on sales
13.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time
Intraday
-1.48%
1 week
4.46%
1 month
-8.16%
1 year
-29.53%
YTD
-23.09%
QTD
-7.71%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$9.66B
Gross profit
$7.25B
Operating income
$1.32B
Net income
$1.17B
Gross margin
75%
Net margin
12.1%
BIIB's operating income has dropped by 64% year-on-year but it is up by 2% since the previous quarter
Biogen's net income has shrunk by 63% YoY
Biogen's operating margin has plunged by 62% YoY but it has increased by 3.8% from the previous quarter
Biogen's net margin has plunged by 61% YoY but it has increased by 2.5% from the previous quarter

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
BIIB P/E details
P/E
24.72
P/B
1.9
P/S
2.99
EV/EBIT
26.35
EV/EBITDA
18.81
EV/Sales
3.61
The EPS has plunged by 63% YoY
The P/E is 52% above the 5-year quarterly average of 16.5
BIIB's price to book (P/B) is 42% lower than its 5-year quarterly average of 3.3 and 23% lower than its last 4 quarters average of 2.5
The equity has grown by 10% YoY and by 2.8% from the previous quarter
The stock's price to sales (P/S) is 18% less than its last 4 quarters average of 3.7 and 13% less than its 5-year quarterly average of 3.5
Biogen's revenue has decreased by 4.4% YoY

Efficiency

How efficient is Biogen business performance
The ROE has plunged by 67% YoY and by 2.5% from the previous quarter
Biogen's return on assets has shrunk by 65% YoY
The ROS has plunged by 62% YoY but it has grown by 3.8% from the previous quarter
The ROIC has plunged by 61% YoY but it has grown by 6% from the previous quarter

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 134% more than the total liabilities
The company's quick ratio has shrunk by 59% YoY but it rose by 3.3% QoQ
The current ratio has contracted by 35% YoY but it has grown by 5% from the previous quarter
Biogen's debt is 54% less than its equity
The equity has grown by 10% YoY and by 2.8% from the previous quarter
The debt to equity has decreased by 8% from the previous quarter and by 4.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.